Reported Sunday, Crinetics Presents Phase 2 Data For Atumelnant In CAH Showing 67% Mean Reduction In Androstenedione Levels With 88% Of Participants Achieving Physiologic Glucocorticoid Dose At Week 12
CRINETICS PHARMACEUTICALS, INC.
CRINETICS PHARMACEUTICALS, INC. CRNX | 0.00 |
- Data show investigational atumelnant drove sustained androgen reductions while enabling lowering of glucocorticoid supplementation to physiologically normal levels in adults with classic CAH
- New results from the Phase 1b/2a ACTH-dependent Cushing's syndrome trial also presented, showing atumelnant rapidly lowered early morning cortisol and normalized urinary free cortisol levels even at lower d